Advertisement

Schizophrenia and Its Sequelae

  • Mary V. SeemanEmail author
Chapter
  • 723 Downloads

Abstract

Background: Schizophrenia is considered to be one of the most serious of mental illnesses in terms of the patient, the patient’s family, and the patient’s community.

Aim: The aim of this chapter is to introduce the reader into the realities of life with schizophrenia.

Method: The literature on schizophrenia is vast and cannot be easily reviewed. Topics relevant to quality of life in schizophrenia were first determined via consultation with clinicians, researchers, and experts by experience. The most pertinent and up-to-date references were then selected and summarized.

Results: Schizophrenia, its risk factors, demographics, life course, sequelae, and treatment all point to many interactive factors that can, and do, undermine both subjective and objective quality of life.

Conclusion: The purpose of researching quality of life issues in schizophrenia is to better understand how best to intervene clinically and how best to help patients with this diagnosis meet their life goals.

Keywords

Antipsychotic Drug Negative Symptom Assertive Community Treatment Social Defeat Repetitive Thought 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry. 2010;2:417–28.CrossRefGoogle Scholar
  2. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.Google Scholar
  3. Bach P, Hayes SC. The use of acceptance and commitment therapy to prevent the rehospitalization of psychotic patients: a randomized controlled trial. J Consult Clin Psychol. 2002;70:1129–39.CrossRefPubMedGoogle Scholar
  4. Barker V, Gumley A, Schwannauer M, Lawrie SM. An integrated biopsychosocial model of childhood maltreatment and psychosis. Br J Psychiatry. 2015;206:177–80.CrossRefPubMedGoogle Scholar
  5. Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, de Haan L. The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. Schizophr Bull. 2013;39:1242–51.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O’Brien R, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry. 2001;158:1706–13.CrossRefPubMedGoogle Scholar
  7. Bengtsson-Tops A, Ehliasson K. Victimization in individuals suffering from psychosis: a swedish cross-sectional study. J Psychiatr Ment Health Nurs. 2012;19:23–30.CrossRefPubMedGoogle Scholar
  8. Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci. 2012;1262:56–66.CrossRefPubMedGoogle Scholar
  9. Bergink V, Gibney SM, Drexhage HA. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry. 2014;75:324–31.CrossRefPubMedGoogle Scholar
  10. Bond GR, Drake RE, Becker DR. An update on randomized controlled trials of evidence-based supported employment. Psychiatr Rehabil J. 2008;31:280–90.CrossRefPubMedGoogle Scholar
  11. Braga RJ, Reynolds GP, Siris SG. Anxiety comorbidity in schizophrenia. Psychiatry Res. 2013;210:1–7.CrossRefPubMedGoogle Scholar
  12. Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P. Suicide in schizophrenia. Expert Rev Neurother. 2010;10:1153–64.CrossRefPubMedGoogle Scholar
  13. Charrier N, Chevreul K, Durand-Zaleski I. The cost of schizophrenia: a literature review. Encéphale. 2013;39 Suppl 1:S49–56.CrossRefPubMedGoogle Scholar
  14. Cichocki Ł, Cechnicki A, Franczyk-Glita J, Błądziński P, Kalisz A, Wroński K. Quality of life in a 20-year follow-up study of people suffering from schizophrenia. Compr Psychiatry. 2015;56:133–40.CrossRefPubMedGoogle Scholar
  15. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry. 2012;72:811–6.CrossRefPubMedGoogle Scholar
  16. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010;36:48–70.CrossRefPubMedGoogle Scholar
  17. Doherty JL, O’Donovan MC, Owen MJ. Recent genomic advances in schizophrenia. Clin Genet. 2012;81:103–9.CrossRefPubMedGoogle Scholar
  18. Duhig M, Patterson S, Connell M, Foley S, Capra C, Dark F, Gordon A, Singh S, Hides L, McGrath JJ, Scott J. The prevalence and correlates of childhood trauma in patients with early psychosis. Aust N Z J Psychiatry. 2015;49:651–9.CrossRefPubMedGoogle Scholar
  19. Elis O, Caponigro JM, Kring AM. Psychosocial treatments for future directions. Clin Psychol Rev. 2013;33:914–28.CrossRefPubMedPubMedCentralGoogle Scholar
  20. European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI). Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull. 2014;40:729–36.CrossRefGoogle Scholar
  21. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res. 1982;17:319–34.CrossRefPubMedGoogle Scholar
  22. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74:400–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Gerlinger G, Hauser M, Hert M, Lacluyse K, Wampers M, Correll CU. Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions. World Psychiatry. 2013;12:155–64.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Ghoreishi A, Kabootvand S, Zangani E, Bazargan-Hejazi S, Ahmadi A, Khazaie H. Prevalence and attributes of criminality in patients with schizophrenia. J Inj Violence Res. 2015;7:7–12.PubMedPubMedCentralGoogle Scholar
  25. Gilmer TP, Stefancic A, Katz ML, Sklar M, Tsemberis S, Palinkas LA. Fidelity to the housing first model and effectiveness of permanent supported housing programs in California. Psychiatr Serv. 2014;65:1311–7.CrossRefPubMedGoogle Scholar
  26. Greve J, Nielsen LH. Useful beautiful minds-an analysis of the relationship between schizophrenia and employment. J Health Econ. 2013;32:1066–76.CrossRefPubMedGoogle Scholar
  27. Gur RE, Loughead J, Kohler CG, Elliott MA, Lesko K, Ruparel K, et al. Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry. 2007;64:1356–66.CrossRefPubMedGoogle Scholar
  28. Harrop C, Trower P. Why does schizophrenia develop at late adolescence? Clin Psychol Rev. 2001;21:241–65.CrossRefPubMedGoogle Scholar
  29. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13:318–78.CrossRefPubMedGoogle Scholar
  30. Horan WP, Kern RS, Tripp C, Hellemann G, Wynn JK, Bell M, et al. Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res. 2011;45:1113–22.CrossRefPubMedPubMedCentralGoogle Scholar
  31. Huguelet P, Koellner V, Boulguy S, Nagalingum K, Amani S, Borras L, Perroud N. Effects of an assertive community program in patients with severe mental disorders and impact on their families. Psychiatry Clin Neurosci. 2012;66:328–36.CrossRefPubMedGoogle Scholar
  32. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748–51.CrossRefPubMedGoogle Scholar
  33. Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med. 2013;43:239–57.CrossRefPubMedGoogle Scholar
  34. Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D, Boydell J, et al. Incidence of schizophrenia and other psychoses in England, 1950–2009: a systematic review and meta-analyses. PLoS One. 2012;7:e31660.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Kreyenbuhl J, Buchanan R, Kelly D, Noel J, Boggs D, Fischer B, et al. The 2009 schizophrenia patient outcomes research team (PORT) psychopharmacological treatment recommendations. Int Clin Psychopharmacol. 2011;26:e54–5.CrossRefGoogle Scholar
  36. Krumm S, Becker T, Wiegand-Grefe S. Mental health services for parents affected by mental illness. Curr Opin Psychiatry. 2013;26:362–8.CrossRefPubMedGoogle Scholar
  37. Kylmä J, Juvakka T, Nikkonen M, Korhonen T, Isohanni M. Hope and schizophrenia: an integrative review. J Psychiatr Ment Health Nurs. 2006;13:651–64.CrossRefPubMedGoogle Scholar
  38. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–48.CrossRefPubMedGoogle Scholar
  39. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.CrossRefPubMedGoogle Scholar
  40. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMedGoogle Scholar
  41. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci. 2002;25:409–32.CrossRefPubMedGoogle Scholar
  42. Lin A, Wood SJ, Nelson B, Beavan A, McGorry P, Yung AR. Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. Am J Psychiatry. 2015;172:249–58.CrossRefPubMedGoogle Scholar
  43. Lodge DJ, Grace AA. Developmental pathology, dopamine, stress and schizophrenia. Int J Dev Neurosci. 2011;29:207–13.CrossRefPubMedGoogle Scholar
  44. Lucksted A, McFarlane W, Downing D, Dixon L. Recent developments in family psychoeducation as an evidence-based practice. J Marital Fam Ther. 2012;38:101–21.CrossRefPubMedGoogle Scholar
  45. Matthews PR, Eastwood SL, Harrison PJ. Reduced myelin basic protein and actin-related gene expression in visual cortex in schizophrenia. PLoS One. 2012;7, e38211.CrossRefPubMedPubMedCentralGoogle Scholar
  46. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600–10.CrossRefPubMedGoogle Scholar
  47. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 2009;66:811–22.CrossRefPubMedPubMedCentralGoogle Scholar
  48. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37:4–15.CrossRefPubMedGoogle Scholar
  49. Niemi LT, Suvisaari JM, Haukka JK, Lönnqvist JK. Childhood predictors of future psychiatric morbidity in offspring of mothers with psychotic disorder results from the Helsinki High-Risk Study. Br J Psychiatry. 2005;186:108–14.CrossRefPubMedGoogle Scholar
  50. Palmer BW, Sirkin MA, Depp CA, Glorioso DK, Jeste DV. Wellness within illness: happiness in schizophrenia. Schizophr Res. 2014;159:151–6.CrossRefPubMedGoogle Scholar
  51. Rus-Calafell M, Gutiérrez-Maldonado J, Ribas-Sabaté J. A virtual reality integrated program for improving social skills in patients with schizophrenia: a pilot study. J Behav Ther Exp Psychiatry. 2014;45:81–9.CrossRefPubMedGoogle Scholar
  52. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rössler A, et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry. 2015;30:388–404.CrossRefPubMedGoogle Scholar
  53. Schultz SK, Miller DD, Oliver SE, Arndt S, Flaum M, Andreasen NC. The life course of schizophrenia: age and symptom dimensions. Schizophr Res. 1997;23:15–23.CrossRefPubMedGoogle Scholar
  54. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10:515–31.CrossRefPubMedGoogle Scholar
  55. Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2009;35:937–48.CrossRefPubMedGoogle Scholar
  56. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci Ther. 2011;17:118–32.CrossRefPubMedGoogle Scholar
  57. Seeman MV. Intervention to prevent child custody loss in mothers with schizophrenia. Schizophr Res Treatment. 2012a;2012:796763.CrossRefPubMedGoogle Scholar
  58. Seeman MV. Women and psychosis. Womens Health. 2012b;8:215–24.Google Scholar
  59. Selten JP, van der Ven E, Rutten BP, Cantor-Graae E. The social defeat hypothesis of schizophrenia: an update. Schizophr Bull. 2013;39:1180–6.CrossRefPubMedPubMedCentralGoogle Scholar
  60. Sheffield JM, Gold JM, Strauss ME, Carter CS, MacDonald III AW, Ragland JD, et al. Common and specific cognitive deficits in schizophrenia: relationships to function. Cogn Affect Behav Neurosci. 2014;14:161–74.CrossRefPubMedPubMedCentralGoogle Scholar
  61. Shepherd AM, Laurens KR, Matheson SL, Carr VJ, Green MJ. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev. 2012;36:1342–56.CrossRefPubMedGoogle Scholar
  62. Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for psychosis. Schizophr Res. 2010;116:168–72.CrossRefPubMedGoogle Scholar
  63. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40:181–91.CrossRefPubMedGoogle Scholar
  64. Song X, Fan X, Song X, Zhang J, Zhang W, Li X, et al. Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight. Schizophr Res. 2013;150:269–73.CrossRefPubMedGoogle Scholar
  65. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460:744–7.PubMedPubMedCentralGoogle Scholar
  66. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187–92.CrossRefPubMedGoogle Scholar
  67. Suvisaari JM, Taxell-Lassas V, Pankakoski M, Haukka JK, Lönnqvist JK, Häkkinen LT. Obstetric complications as risk factors for schizophrenia spectrum psychoses in offspring of mothers with psychotic disorder. Schizophr Bull. 2013;39:1056–66.CrossRefPubMedGoogle Scholar
  68. Tejkalová H, Kaiser M, Klaschka J, Stastny F. Does neonatal brain ischemia induce schizophrenia-like behavior in young adult rats? Physiol Res. 2007;56:815–23.PubMedGoogle Scholar
  69. Van Dorn R, Volavka J, Johnson N. Mental disorder and violence: is there a relationship beyond substance use? Soc Psychiatry Psychiatr Epidemiol. 2012;47:487–503.CrossRefPubMedGoogle Scholar
  70. Vargas G, Strassnig M, Sabbag S, Gould F, Durand D, Stone L, et al. The course of vocational functioning in patients with schizophrenia: Re-examining social drift. Schizophr Res Cogn. 2014;1:e41–6.CrossRefPubMedPubMedCentralGoogle Scholar
  71. Wykes T, Reeder C, Landau S, Everitt B, Knapp M, Patel A, Romeo R. Cognitive remediation therapy in schizophrenia randomised controlled trial. Br J Psychiatry. 2007;190:421–7.CrossRefPubMedGoogle Scholar
  72. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34:523–37.CrossRefPubMedGoogle Scholar
  73. Yao L, Lui S, Liao Y, Du M, Hu N, Thomas JA, Gong Q. White matter deficits in first episode schizophrenia: an activation likelihood estimation meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:100–6.CrossRefPubMedGoogle Scholar
  74. Zhang R, Wei Q, Kang Z, Zalesky A, Li M, Xu Y, et al. Disrupted brain anatomical connectivity in medication-naïve patients with first-episode schizophrenia. Brain Struct Funct. 2015;220:1145–59.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Psychiatry, The Institute of Medical ScienceUniversity of TorontoTorontoCanada

Personalised recommendations